文献速递糖尿病肥胖与代谢综合征

司美格鲁肽在不同慢性肾脏病分期中的代谢与血压结局:FLOW试验事后分析

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-11-04

FLOW试验事后分析评估司美格鲁肽1.0 mg对3533例2型糖尿病合并慢性肾脏病患者的HbA1c、体重和血压的影响。结果显示,与安慰剂相比,司美格鲁肽在各eGFR/UACR分层中均显著降低HbA1c和体重,且疗效无显著交互作用;在较低eGFR/较高UACR组中收缩压改善更明显。

要点

  • 司美格鲁肽降低HbA1c和体重的作用不受基线eGFR或UACR影响。
  • 在较低eGFR/较高UACR患者中,司美格鲁肽对收缩压的改善更显著。
  • 治疗效应在各eGFR/UACR分层间无显著交互作用。

核心结论

  • 司美格鲁肽改善血糖控制和体重,无论基线eGFR或UACR如何,并在较低eGFR/较高UACR类别中改善收缩压。

研究设计与样本

  • FLOW试验的事后分析,为国际、双盲、随机、3b期临床试验,纳入3533例2型糖尿病合并慢性肾脏病的成人。
  • 比较司美格鲁肽1.0 mg与安慰剂(均在标准治疗基础上)从基线至第104周的变化。
  • 按基线eGFR(≥60、≥45至<60、≥30至<45、<30 mL/min/1.73 m2)和UACR(<30、30至<300、≥300 mg/g)分层。
  • 采用协方差分析,以基线eGFR/UACR为协变量,并包含治疗组与eGFR/UACR类别的交互项。

主要发现

  • 与安慰剂组相比,司美格鲁肽组从基线至第104周HbA1c降低更显著(各eGFR/UACR组的ETD范围:−0.7%至−1.0%;所有p < 0.0001)。
  • 与安慰剂组相比,司美格鲁肽组体重降低更显著(ETD:−2.5 kg至−4.6 kg;除UACR < 30组外所有p < 0.0001)。
  • 基线eGFR较低/UACR较高类别的患者接受司美格鲁肽治疗后,收缩压改善比安慰剂组更明显。
  • 交互分析显示,对于任何结局,治疗效果均不因基线eGFR/UACR而存在显著差异。

临床怎么用

  • 对于2型糖尿病合并慢性肾脏病患者,司美格鲁肽的降糖和减重疗效不依赖于基线eGFR或UACR水平。
  • 在较低eGFR或较高UACR的患者中,可考虑司美格鲁肽对收缩压的额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims To assess changes in glycated haemoglobin (HbA1c), body weight, and systolic/diastolic blood pressure (SBP/DBP) by chronic kidney disease (CKD) and albuminuria categories in a post hoc analysis of FLOW, an international, double-blind, randomized, phase 3b clinical trial of adults with CKD and Type 2 diabetes (T2D). Materials and Methods We evaluated the effect of semaglutide 1.0 mg versus placebo (in addition to standard of care) on changes in HbA1c, body weight, SBP, and DBP from baseline to Week 104 stratified by baseline estimated glomerular filtration rate (eGFR; ≥ 60, ≥ 45 to < 60, ≥ 30 to < 45, < 30 mL/min/1.73 m2) and urine albumin-to-creatinine ratio (UACR; < 30, 30 to < 300, and ≥ 300 mg/g). Outcomes were analysed using analysis of covariance with baseline eGFR/UACR as covariates and an interaction term for treatment group by eGFR/UACR categories. We calculated the estimated treatment difference (ETD) between the semaglutide and placebo groups. Results FLOW included 3533 participants. Compared with participants assigned placebo, those assigned semaglutide had greater reductions in HbA1c (ETD range across eGFR/UACR groups: −0.7% to −1.0%; all p < 0.0001) and body weight (ETD: −2.5 kg to −4.6 kg; all p < 0.0001 except UACR < 30) from baseline to Week 104. Participants with lower baseline eGFR/higher UACR categories treated with semaglutide also had greater improvements in SBP than those receiving placebo. In interaction analyses, the treatment effect did not differ significantly by baseline eGFR/UACR for any of the outcomes. Conclusions Semaglutide improves glycaemic control and weight, regardless of baseline eGFR or UACR, and SBP in lower eGFR/higher UACR categories.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。